Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.

For Immediate Release Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog.